Immunohistochemical Staining for Claudin-1 Can Help Distinguish Meningiomas From Histologic Mimics

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
American Journal of Clinical Pathology (Impact Factor: 2.51). 03/2006; 125(2):203-8. DOI: 10.1309/G659-FVVB-MG7U-4RPQ
Source: PubMed


The histologic distinction between meningiomas and other tumors of the central nervous system occasionally can be difficult. Claudin-1 is a tight junction-associated protein recently shown to be expressed in anaplastic meningiomas. The purpose of this study was to determine whether immunohistochemical staining for claudin-1 could help distinguish meningiomas from histologic mimics, compared with commonly used markers. Tissue sections from 10 meningothelial meningiomas, 20 fibrous meningiomas, 10 atypical meningiomas, 7 solitary fibrous tumors of the meninges, 5 meningeal hemangiopericytomas, and 7 vestibular schwannomas were stained immunohistochemically for claudin-1, epithelial membrane antigen, S-100 protein, CD34, and glial fibrillary acidic protein. In total, 21 (53%) of 40 meningiomas were immunoreactive for claudin-1, whereas none of the other tumors were positive. In contrast, there was considerable overlap in the distribution of the other antibodies evaluated. Claudin-1 seems to be a specific marker for meningiomas in this context. Although its sensitivity is relatively low, claudin-1 may be helpful in a panel of immunostains to distinguish meningiomas from histologic mimics.

10 Reads
  • Source
    • "EMA is widely used in clinical practice to confirm the diagnosis of meningiomas. Unfortunately, EMA is not tumor-specific; therefore, new diagnostic markers for meningiomas are constantly pursued [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Meningiomas are common intracranial tumors. Recently, histogenetic and phenotypic similarities between meningiomas and mesotheliomas have been proposed. We were interested in whether these similarities are reflected on the immunohistochemical level, which would add new potentially diagnostic markers for meningiomas. Methods. The expression of mesothelioma-related markers (D2-40, Calretinin, Keratin 5/6, WT1, and Methotheioma-Ab1) was investigated in 87 cases of meningiomas and compared to EMA expression. Results. 73.6% of meningioma cases were grade I, 20.7% were grade II, and 5.7% were grade III. 83.9% of meningioma cases were classical and 16.1% had special nonmeningothelial features. D2-40 was expressed in 37.9% of cases and was significantly restricted to classical meningiomas. Calretinin and WT1 were negative while Keratin 5/6 and Mesothelioma-Ab1 were weakly expressed in classical variants (5.7% and 3.4%, resp.). EMA was consistently expressed in all cases. Its expression was significantly higher than that of mesothelioma-related markers; this held true also when D2-40 expression was considered separately. Conclusions. Mesothelioma-related markers are not extensively expressed in meningiomas, a finding that argues against their proposed histogenetic and phenotypic similarities. Compared to EMA, the significantly lower expression of mesothelioma-related markers and their restricted expression to classical meningioma variants hamper their potential future use as diagnostic markers for meningioma.
    BioMed Research International 04/2014; 2014(6):968794. DOI:10.1155/2014/968794 · 2.71 Impact Factor
  • Source
    • "Immunohistochemistry performed on the tissue from the first excision of the tumour in 1999 was positive for both EMA and CD34, and was confirmed by recent re-staining. However, neither marker is entirely specific: typical figures are that immunoreactivity for EMA is seen in 95% of meningiomas and 20–29% of meningeal SFT/HPC, yet immunoreactivity for CD34 is seen in all SFT, 60% of HPCs, 40% of fibrous meningiomas and 60% of atypical meningiomas (Hahn et al, 2006). Based on electron microscopy findings, the ultrastructural features were not well preserved and were not distinctive. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Meningiomas are the most common primary intracranial tumours, with ∼3% meeting current histopathologic criteria for malignancy. Methods: In this study, we explored the transcriptome of meningiomas using RNA-Seq. Results: Inversion-mediated fusions between two adjacent genes, NAB2 and STAT6, were detected in one malignant tumour, creating two novel in-frame transcripts that were validated by RT–PCR and Sanger sequencing. Conclusion: Gene fusions of NAB2-STAT6 were recently implicated in the pathogenesis of solitary fibrous tumours; our study suggested that similar fusions may also have a role in a malignant meningioma with unusual histopathologic features.
    British Journal of Cancer 07/2013; 109(4). DOI:10.1038/bjc.2013.395 · 4.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diagnostic neuro-oncology practice has benefited in the last 2 decades from the incorporation of, and recent advances in, immunohistochemistry (IHC). Although the mainstay of brain tumor diagnosis including its grading remains conventional hematoxylin-eosin (H&E)-stained histology, it is no doubt that IHC plays a major role in differential diagnosis and in improving the diagnostic accuracy. It is generally used for purposes of (1) identifying tumor cell type/origin, (2) assessing cell proliferation potential, (3) evaluating the boundary between tumor and the surrounding tissue (i.e., tumor “margin”), and (4) excluding reactive processes (e.g., demyelinating and infectious diseases). In the future, novel antibodies utilized as prognostic, predictive markers and as potential therapeutic targets for brain tumors will be developed.
Show more


10 Reads
Available from